Revive Therapeutics Files for FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation
23 nov. 2021 06h00 HE
|
Revive Therapeutics Ltd.
TORONTO, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta Variant
16 nov. 2021 06h00 HE
|
Revive Therapeutics Ltd.
TORONTO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research...
Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of Psilocybin Microneedle Patch
03 nov. 2021 07h00 HE
|
Revive Therapeutics Ltd.
Building specialty psilocybin-based product pipeline Evaluating potential for neuropsychiatric indications for clinical studies in 2022 TORONTO, Nov. 03, 2021 (GLOBE NEWSWIRE) --...
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19
26 oct. 2021 08h15 HE
|
Revive Therapeutics Ltd.
DSMB support in continuing the Phase 3 clinical trial; No serious adverse events and safety concerns reported to date.Phase 3 clinical trial to incorporate viral load testing for a minimum of 300...
Revive Therapeutics Included in AdvisorShares® Newly Launched Psychedelics ETF
21 sept. 2021 09h45 HE
|
Revive Therapeutics Ltd.
TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research...
Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer
17 août 2021 17h46 HE
|
Revive Therapeutics Ltd.
Novel discovery and research originated from Universidad Central del Caribe and St. Jude Children’s Research HospitalMedicinal mushroom compound with anticancer activities that have minimal effects on...
Revive Confirms No Material Undisclosed Information
12 août 2021 08h12 HE
|
Revive Therapeutics Ltd.
TORONTO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (Frankfurt:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Provides Update on Psychedelics Clinical Product Pipeline
10 août 2021 07h48 HE
|
Revive Therapeutics Ltd.
Focusing on novel uses, production and delivery forms of psilocybin as a next generation solution for mental illness, substance abuse and neurological disordersAdvancing to FDA clinical studies for...
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19
15 juil. 2021 13h31 HE
|
Revive Therapeutics Ltd.
Phase 3 clinical trial ongoing with next DSMB meeting at 600 completed patients.Currently at 41 clinical sites and to engage a minimum of 50 clinical sites.Aim to complete enrollment in Q3-2021 and...
Revive Therapeutics Approved to Trade on the OTCQB Market
25 juin 2021 15h09 HE
|
Revive Therapeutics Ltd.
TORONTO, June 25, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, FRANKFURT: 31R), a specialty life sciences company focused on the research and...